Lumos Pharma’s (LUMO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lumos Pharma (NASDAQ:LUMO) in a research report released on Friday, Benzinga reports. They currently have a $28.00 price target on the stock.

Several other research analysts also recently weighed in on the company. Oppenheimer dropped their price target on Lumos Pharma from $16.00 to $13.00 and set an outperform rating for the company in a research note on Friday, August 2nd. EF Hutton Acquisition Co. I upgraded Lumos Pharma to a strong-buy rating in a research note on Tuesday.

Lumos Pharma Trading Up 2.6 %

Shares of NASDAQ:LUMO opened at $3.94 on Friday. The stock has a 50 day moving average of $3.03 and a 200 day moving average of $2.68. The company has a market cap of $31.99 million, a PE ratio of -0.86 and a beta of 0.78. Lumos Pharma has a 12-month low of $1.37 and a 12-month high of $4.55.

Lumos Pharma (NASDAQ:LUMO) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.33. The company had revenue of $0.49 million during the quarter. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. During the same quarter last year, the firm posted ($1.09) earnings per share. Equities research analysts predict that Lumos Pharma will post -2.56 earnings per share for the current fiscal year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.